A randomized, double blind, placebo-controlled, crossover, proof of concept study to evaluate the effectiveness and safety of carisbamate in the treatment of essential tremor.

Trial Profile

A randomized, double blind, placebo-controlled, crossover, proof of concept study to evaluate the effectiveness and safety of carisbamate in the treatment of essential tremor.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Essential tremor
  • Focus Therapeutic Use
  • Sponsors Ortho-McNeil
  • Most Recent Events

    • 01 Aug 2012 Company (SK Life Science) added as an association and lead centre as reported by ClinicalTrials.gov record.
    • 03 Mar 2010 Results published in Movement Disorders.
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top